Trinity Capital Inc. has committed $50 million in growth capital to Cala Health, a bioelectronic medicine company that develops wearable neuromodulation therapies for tremor disorders. The funding will support the commercial expansion of Cala Health’s Cala kIQ® System, an FDA‑cleared device that delivers individualized nerve stimulation to manage hand tremors in patients with essential tremor and Parkinson’s disease.
Cala Health’s latest FDA clearance on April 16, 2026, for its updated Cala kIQ Plus system—an enhanced version of the original device—provides a strong backdrop for the investment. The growth capital is structured as a debt facility, though the specific terms such as interest rate and maturity are not disclosed. The commitment follows Cala Health’s successful Series D round on October 20, 2025, which raised an undisclosed amount and brings the company’s total funding to between $257 million and $263 million across eight rounds.
Trinity Capital’s strategy to partner with high‑growth, technology‑driven life‑sciences companies is reinforced by this deal. The firm reported a Q4 2025 earnings per share of $0.52, beating analyst expectations of $0.51, and a Q1 2025 net investment income of $32.4 million. In Q1 2026, Trinity Capital funded $306 million of its $395 million in new commitments, underscoring its capacity to support sizable financing initiatives.
"Cala Health has developed a therapy that we believe is simple, personalized, and effective for patients," said Rob Lake, Senior Managing Director, Life Sciences at Trinity Capital. "We are proud to partner with a company that is delivering meaningful improvements in patients' daily lives and look forward to supporting their continued growth and commercial expansion."
"We are pleased to partner with the Trinity team to optimize our capital structure," said Cala CEO Deanna Harshbarger. "This collaboration enhances our ability to accelerate commercial expansion and product innovation, advancing Cala TAPS® therapy to impact the lives of essential tremor and Parkinson's disease patients."
"Cala continues to elevate the patient experience and therapy outcomes by advancing wearable neuromodulation technology that treats action hand tremor in essential tremor and Parkinson's disease. The Cala kIQ Plus system gives patients more control over how, when and where TAPS Therapy is delivered for tremor management," said Cala CEO Deanna Harshbarger.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.